For instance, pretreatment PROs were found to be independent prognostic markers for progression-free survival (PFS) in patients diagnosed with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer treated with abemaciclib (22). This evidence concerns the gene ERBB2 and breast carcinoma.